Sonrotoclax is a second-generation BCL2 inhibitor that is more potent than venetoclax. Early data on a combination of sonrotoclax plus zanubrutinib for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL / SLL) is very promising. Clinical trials testing this combination are open and enrolling patients.
In this interview, Dr. Mazyar Shadman from Fred Hutchinson Cancer Center discusses current clinical trials using fixed-duration combination therapies taken orally. Dr. Constantine Tam from Alfred Health and Monash University and colleagues presented one of the studies discussed at the American Society for Hematology (ASH) Annual Meeting in 2023.
Read the full article on CLL Society's website at: cllsociety.org...
__________________________________________________________________________________________
CLL Society Website: cllsociety.org/
Facebook: / cllsociety
Twitter: / cllsociety
LinkedIn: / cll-society